Literature DB >> 17047672

Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats.

Yi-Ling Yang1, Po-Kuan Chao, Long-Sun Ro, Yu-Yuan P Wo, Kwok-Tung Lu.   

Abstract

Recent results show that brain glucocorticoids are involved in the dysregulation of fear memory extinction in post-traumatic stress disorder patients. The present study was aimed to elucidate the possible mechanism of glucocorticoids on the conditioned fear extinction. To achieve these goals, male SD rats, fear-potentiated startle paradigm, and Western blot were used. We found that (1) systemic administration of the synthetic glucocorticoid agonist dexamethasone (DEX) facilitated extinction of conditioned fear in a dose-dependent manner (0.05, 0.1, 0.5, or 1.0 mg/kg, i.p.); (2) systemic administration of the glutamate NMDA receptor antagonist (+/-)-HA966 (6.0 mg/kg, i.p.) and intra-amygdala infusion of the NMDA receptor antagonists MK801 (0.5 ng/side, bilaterally) or D,L-2-amino-5-phosphonovaleric acid (AP5, 2.0 ng/side, bilaterally) blocked the DEX facilitation effect; (3) the corticosteroid synthesis inhibitor metyrapone (25 mg/kg. s.c.) blocked extinction and this was prevented by co-administration of NMDA receptor agonist D-cycloserine (DCS, 5.0 mg/kg, i.p.); (4) co-administration of DEX and DCS in subthreshold doses provided a synergistic facilitation effect on extinction (0.2 and 5 mg/kg, respectively). Control experiments indicated that co-administration of DEX and DCS did not alter the expression of conditioned fear and the effect was not due to lasting damage to the amygdala. These results suggest that glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047672     DOI: 10.1038/sj.npp.1301215

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  35 in total

Review 1.  Pharmacological enhancement of drug cue extinction learning: translational challenges.

Authors:  K M Kantak; B Á Nic Dhonnchadha
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  Neural mechanisms of extinction learning and retrieval.

Authors:  Gregory J Quirk; Devin Mueller
Journal:  Neuropsychopharmacology       Date:  2007-09-19       Impact factor: 7.853

3.  Intra-amygdaloid infusion of Ginkgo biloba leaf extract (EGb761) facilitates fear-potentiated startle in rats.

Authors:  Yi-Ling Yang; Chia-Wen Hsieh; Yu-Yuan P Wo; Yi-Chung Yang; Kwok-Tung Lu
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

4.  Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.

Authors:  Joseph F McGuire; Adam B Lewin; Daniel A Geller; Ashley Brown; Kesley Ramsey; Jane Mutch; Andrew Mittelman; Jamie Micco; Cary Jordan; Sabine Wilhelm; Tanya K Murphy; Brent J Small; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2012-08

5.  Dexamethasone Treatment Leads to Enhanced Fear Extinction and Dynamic Fkbp5 Regulation in Amygdala.

Authors:  Takehito Sawamura; Torsten Klengel; Antonio Armario; Tanja Jovanovic; Seth D Norrholm; Kerry J Ressler; Raül Andero
Journal:  Neuropsychopharmacology       Date:  2015-07-15       Impact factor: 7.853

6.  The role of the dorsal hippocampus on the Ginkgo biloba facilitation effect of fear extinction as assessed with fear-potentiated startle.

Authors:  Yu-Fang Shen; Yu-Hsuan Chou; Yi-Ling Yang; Kwok-Tung Lu
Journal:  Psychopharmacology (Berl)       Date:  2011-03-15       Impact factor: 4.530

Review 7.  Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders.

Authors:  Olena Bukalo; Courtney R Pinard; Andrew Holmes
Journal:  Br J Pharmacol       Date:  2014-07-23       Impact factor: 8.739

8.  Neural Underpinnings of Cortisol Effects on Fear Extinction.

Authors:  Christian Josef Merz; Tanja Christina Hamacher-Dang; Rudolf Stark; Oliver Tobias Wolf; Andrea Hermann
Journal:  Neuropsychopharmacology       Date:  2017-09-26       Impact factor: 7.853

9.  Amygdala volume in patients receiving chronic corticosteroid therapy.

Authors:  E Sherwood Brown; Dixie J Woolston; Alan B Frol
Journal:  Biol Psychiatry       Date:  2007-11-05       Impact factor: 13.382

10.  Preclinical assessment for selectively disrupting a traumatic memory via postretrieval inhibition of glucocorticoid receptors.

Authors:  Stephen M Taubenfeld; Justin S Riceberg; Antonia S New; Cristina M Alberini
Journal:  Biol Psychiatry       Date:  2008-08-16       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.